Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs.
Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3-day ex vivo incubation in the presence of 1000 U/ml of recombinant interleukin-2, lymphocytes from seropositive individuals exhibited a LAK cell response which was equivalent to or greater than that of seronegative controls as measured against Daudi cell targets. LAK cells from seropositive and seronegative donors showed no specific cytolytic activity against gp120-coated or HIV-1-infected targets. However, in the presence of patient sera, significant levels of virus-specific LAK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) were observed. The level of this specific LAK cell-mediated ADCC was greater than that mediated under similar conditions by freshly isolated peripheral blood mononuclear cells. The greatest improvement in ADCC over baseline activity was seen with lymphocytes from AIDS patients after the 3-day ex vivo activation, suggesting that this patient population might benefit the most from adaptive LAK cell therapy.
Tyler
D S
DS
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Stanley
S D
SD
Bartlett
J A
JA
Bolognesi
D P
DP
Weinhold
K J
KJ
D000920:Antibody-Dependent Cell Cytotoxicity / Q000502:physiology*; D002462:Cell Membrane / Q000378:metabolism; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015658:HIV Infections / Q000473:pathology* / Q000821:virology*; D018023:HIV Seronegativity / Q000502:physiology; D006679:HIV Seropositivity / Q000097:blood; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D011994:Recombinant Proteins; D013499:Surface Properties; D014407:Tumor Cells, Cultured
D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D007376:Interleukin-2; D011994:Recombinant Proteins